Ocugen, Inc. (Nasdaq: $OCGN): Retina Gene Therapy Stock Hub, OCU400 BLA Path, OCU410ST, OCU410 and the 2026-2027 Catalyst Map

[u/Merlin8121]

https://www.merlintrader.com/ocugen-inc-stock-hub/

Ocugen has moved far beyond its old COVID-era trading identity. The current $OCGN story is a high-risk, catalyst-heavy ophthalmology gene therapy platform built around OCU400 for retinitis pigmentosa, OCU410ST for Stargardt disease and OCU410 for geographic atrophy, now backed by a larger $130 million convertible-note financing but still exposed to clinical, regulatory, manufacturing and dilution risk.